FDA has designated rexlemestrocel-L a Regenerative Medicine Advanced Therapy (RMAT) for the treatment of chronic low back pain. RMAT designation provides all the benefits of Breakthrough and Fast ...

About GlohCo GlohCo is a healthtech intelligence platform focused on building software and data-driven tools for use across digital health and care delivery environments.

NORTH PALM BEACH, Fla., Jan. 16, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") today announced that it has invested in the common stock of Opendoor ...

In 2025, Baylor Genetics was named an official genetic testing partner of the Child Neurology Society.

Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Sun Pharmaceuticals for UNLOXCYT ™ (cosibelimab-ipdl). UNLOXCYT is the first and ...

About the Emerging Growth Conference The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to ...

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing ...

Craniofacial pain is among the most common chronic pain conditions, affecting more than one-fifth of the U.S. population 1. With this milestone, Curonix advances its mission to drive full-body PNS ...

(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today ...

The stock option awards were granted outside of the Context Therapeutics Inc. 2021 Long-Term Performance Incentive Plan in accordance with Nasdaq Listing Rule 5635 (c) (4).

PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis. Carlsbad, CA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio ...

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of ...